AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21190996
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (HiDAC)
Trial: 16110019
Drug: CI-1033 200
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-1033 200 mg daily for 21 days in a 28-day cycle
Trial: 16110019
Drug: CI-1033 50
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-1033 50 mg daily for 21 days in a 28-day cycle
Trial: 11932085
Drug: Intravenous meperidine/diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous meperidine/diazepam (IVMD)
Trial: 8553820
Drug: metallic implants
RxNorm normalized name: Aluminum metal
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metallic implants
Trial: 25041333
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (LTPP + fluoxetine)
Trial: 25041333
Drug: Fluoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine treatment (20‐60 mg/day)
Trial: 23733915
Drug: High free
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High free fatty acid (FFA) levels (intralipid/heparin-infusion)
Trial: 15083317
Drug: Soy cookies
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy cookies (52 mg isoflavones)
Trial: 9806658
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose megestrol acetate (160 mg/day)
Trial: 9806658
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose megestrol acetate (640 mg/day)
Trial: 8543705
Drug: Cognitive-behavioral relapse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral relapse prevention treatment
Trial: 2622988
Drug: Ethanol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.75 g/kg) after sleep extension
Trial: 402406
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium nasal solution (4% aqueous solution)
Trial: 31369675
Drug: Cervical headgear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical headgear treatment (CH) started at age 7.8 years (Early Group - EG)
Trial: 31369675
Drug: Cervical headgear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical headgear treatment (CH) started at age 9.5 years (Late Group - LG)
Trial: 28894768
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid + 3% hypertonic solution
Trial: 28894768
Drug: 3% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% hypertonic solution
Trial: 17942782
Drug: Sodium ferric
RxNorm normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ferric gluconate complex (1.5 mg/kg)
Trial: 17942782
Drug: Sodium ferric
RxNorm normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ferric gluconate complex (3.0 mg/kg)
Trial: 29969293
Drug: G‐CBT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CBT + ABM
Trial: 29969293
Drug: G‐CBT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CBT + ACT
Trial: 27275618
Drug: Osseointegrated implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osseointegrated implants subjected to 200-cN force
Trial: 27275618
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (implants not subjected to orthodontic force)
Trial: 20216276
Drug: Mediterranean diet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet, physical exercise, and daily oral ingestion of 40 mg of soy isoflavones
Trial: 17711562
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g intravenous paracetamol
Trial: 12966366
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg diclofenac
Trial: 14551147
Drug: Second-generation oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second-generation oral contraceptive (30 microg ethinylestradiol/150 microg levonorgestrel)
Trial: 14551147
Drug: Third-generation oral
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Third-generation oral contraceptive (30 microg ethinylestradiol/150 microg desogestrel)
Trial: 12138364
Drug: Progestagen-only preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestagen-only preparation (150 microg levonorgestrel)
Trial: 12138364
Drug: Progestagen-only preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestagen-only preparation (150 microg desogestrel)
Trial: 9527763
Drug: Indinavir at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir at 1,000 mg every 8 h for 7 1/3 days with fluconazole placebo
Trial: 9527763
Drug: Fluconazole at
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole at 400 mg once daily for 8 days with indinavir placebo
Trial: 9527763
Drug: Indinavir with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir with fluconazole in combination
Trial: 7599543
Drug: Methadone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone at 0.30 mg/kg
Trial: 7599543
Drug: Morphine at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine at 0.30 mg/kg
Trial: 2090769
Drug: mezlocillin 2
RxNorm normalized name: mezlocillin 250 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mezlocillin 2 g i.v. 15 to 20 minutes preoperatively
Trial: 2090769
Drug: cefotetan 2
RxNorm normalized name: cefotetan 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefotetan 2 g i.v. 15 to 20 minutes preoperatively
Trial: 359091
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate dry powder 150 microgram four times daily
Trial: 359091
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate dry powder 100 microgram four times daily
Trial: 359091
Drug: Conventional aerosol
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional aerosol 100 microgram four times daily
Trial: 26892074
Drug: Recipe booklet
RxNorm normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recipe booklet and monthly reminder text messages
Trial: 20661550
Drug: Dopamine D2/D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D2/D3 receptor agonist (pramipexole)
Trial: 20661550
Drug: Dopamine D2/D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D2/D3 receptor antagonist (amisulpride)
Trial: 15831781
Drug: Exenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (10 µg) injected subcutaneously at 0 hours with acetaminophen (1000 mg) ingested at -1, 0, +1, +2, and +4 hours.
Trial: 15831781
Drug: Placebo injected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected subcutaneously at 0 hours with acetaminophen (1000 mg) ingested.
Trial: 16492988
Drug: Prebiotic-supplemented milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic-supplemented milk formula (4.5 g/L)
Trial: 24299553
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (OC) containing 30 μg ethinyl estradiol and 3 mg drospirenone (group I; n = 21)
Trial: 15975313
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with leeching intervention, n = 24
Trial: 29027235
Drug: Commercially reconstructed
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially reconstructed quarter-dose images with no noise reduction
Trial: 29027235
Drug: Full-dose commercial
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose commercial images
Trial: 17546902
Drug: Sulfadoxine/pyrimethamine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine/pyrimethamine monotherapy
Trial: 17546902
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Chloroquine + Sulfadoxine/pyrimethamine)
Trial: 11686428
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg inhaled plus 200 microg intranasal budesonide once daily
Trial: 11686428
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg montelukast plus 10 mg cetirizine once daily
Trial: 9307671
Drug: Calcium-channel antagonists
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-channel antagonists
Trial: 16284750
Drug: Amphetamine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine administration
Trial: 3145528
Drug: Saline (control)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (control) administration
Trial: 26092818
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg once daily) plus trastuzumab and paclitaxel
Trial: 9285305
Drug: 5 alpha-reductase
RxNorm normalized name: 5.alpha.-hydroxy laxogenin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 alpha-reductase inhibitor (finasteride 5 mg/day)
Trial: 7687111
Drug: PRP-OMPC vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-OMPC vaccine
Trial: 3828185
Drug: Extradural phenoperidine
RxNorm normalized name: phenoperidine
DrugBank: Phenoperidine (DB13605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural phenoperidine 2 mg
Trial: 3828185
Drug: Extradural diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural diamorphine 5 mg
Trial: 3828185
Drug: i.m. diamorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. diamorphine 5 mg
Trial: 26236130
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (DFDBA and barrier membrane)
Trial: 26236130
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment + doxycycline group (DFDBA and barrier membrane with local doxycycline)
Trial: 23332533
Drug: Self-monitoring (SM)
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-monitoring (SM) intervention, daily dietary logs for 6 weeks
Trial: 21700946
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (MI) - 4 individual, weekly sessions
Trial: 16703253
Drug: Laser acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser acupuncture (5 mW HeNe laser on 22 acupuncture points for 15 s each) plus cervical collar and a combination of paracetamol and chlormezanone
Trial: 16703253
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser treatment plus cervical collar and a combination of paracetamol and chlormezanone
Trial: 15319718
Drug: Oxandrolone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (10 mg po BID)
Trial: 73912
Drug: Polyglycolic acid
RxNorm normalized name: polyglycolic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyglycolic acid (P.G.A.) suture material
Trial: 26569658
Drug: Ribavirin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (in combination with Sofosbuvir and Velpatasvir)
Trial: 23593314
Drug: Investigator selected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator selected boosted comparator HIV-1 protease inhibitors (CPI-Ritonavir)
Trial: 16920858
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (30 mg daily for 6 months)
Trial: 16920858
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (30 mg daily for 6 months)
Trial: 12943174
Drug: Kyuki‐chouketsu‐in at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kyuki‐chouketsu‐in at a dose of 6.0 g/day (Group K)
Trial: 17436360
Drug: Ergometrine (methylergometrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergometrine (methylergometrine maleate) at a dose of 0.375 mg/day (Group E)
Trial: 10848853
Drug: Aprotinin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (2 x 10^6 units bolus, followed by 0.5 x 10^6 units infusion every 30 min)
Trial: 7034929
Drug: High-dose MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose MTX
Trial: 9332684
Drug: Moderate-dose MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose MTX
Trial: 9332684
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with MTX and CDP
Trial: 12959279
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enalapril and doxazosin
Trial: 2433701
Drug: Griseofulvin, 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin, 125 mg four times daily
Trial: 2433701
Drug: Methisoprinol, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methisoprinol, 1 g four times daily
Trial: 2433701
Drug: Griseofulvin plus
RxNorm normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Griseofulvin plus methisoprinol (dosage schedules as above)
Trial: 2433701
Drug: Placebo, four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, four times daily
Trial: 26271769
Drug: Moderate Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate Light (ML, 230 lx) for 120 min prior to and during exercise (2HEX)
Trial: 26271769
Drug: Moderate Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate Light (ML, 230 lx) for 60 min prior to and during exercise (1HEX)
Trial: 26271769
Drug: Moderate Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate Light (ML, 230 lx) for 60 min prior to exercise (1H)
Trial: 24260184
Drug: Astaxanthin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin supplementation (20 mg/day)
Trial: 18510659
Drug: tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine ER (4 mg)
Trial: 1358231
Drug: 7 mg
RxNorm normalized name: pectin 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg muscimol (GABA agonist)
Trial: 2951501
Drug: SR 270258
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 270258 (2 mg/m2, subcutaneous injections, three times per week for 1 month)
Trial: 22034637
Drug: Pyridorin 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridorin 150 mg twice daily
Trial: 22034637
Drug: Pyridorin 300
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridorin 300 mg twice daily
Trial: 16843455
Drug: metformin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin (1 g twice daily)
Trial: 23835717
Drug: 3D‐CRT APBI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D‐CRT APBI (38.5 Gy in 10 fractions twice daily)
Trial: 23835717
Drug: WBI (42.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBI (42.5 Gy in 16 or 50 Gy in 25 daily fractions ± boost irradiation)
Trial: 19193900
Drug: D(2) receptor
RxNorm normalized name: Vitamin D-2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D(2) receptor agonist bromocriptine
Trial: 1428296
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no drug administration)
Trial: 8498314
Drug: Amlodipine 2.5
RxNorm normalized name: amlodipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 2.5 mg daily
Trial: 15343191
Drug: Amlodipine (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (dose > or = 0.06 mg/kg per day)
Trial: 9301693
Drug: Bicalutamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (50 mg once daily) plus LHRH‐A
Trial: 9301693
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg three times daily) plus LHRH‐A
Trial: 8359186
Drug: Thymoxamine 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoxamine 0.5% solution
Trial: 8359186
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (mannitol)
Trial: 8359186
Drug: Ibopamine 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 1% solution
Trial: 24561970
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day IV glutamine
Trial: 24561970
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day enteral glutamine
Trial: 24561970
Drug: 15 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/day IV and 15 g/day enteral glutamine
Trial: 17452062
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (Donepezil and Control)
Trial: 12790207
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at target concentrations of 150, 225, and 300 ng mL(‐1)
Trial: 12790207
Drug: Propofol added
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol added to alfentanil infusion
Trial: 12790207
Drug: Alfentanil target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil target concentration cA0 = 1240 (51) ng mL(‐1) and propofol concentration cP0 = 5.21 (0.36) microg mL(‐1)
Trial: 1773095
Drug: Exogenous melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous melatonin (5 mg) at bedtime (2200 hr) for 3 weeks
Trial: 1773095
Drug: Exogenous melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous melatonin (7 mg at 2100 hr)
Trial: 7046937
Drug: Propranolol-hydrochlorothiazide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol-hydrochlorothiazide combination (n = 47)
Trial: 24948511
Drug: Empagliflozin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (25 mg once daily, orally)
Trial: 24948511
Drug: Glimepiride (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1-4 mg once daily, orally)
Trial: 20104069
Drug: Citalopram (20‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20‐40 mg/day)
Trial: 11488362
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR (75-225 mg/day)
Trial: 3055720
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 1 g carnitine orally for one week and 1 x 1 g carnitine for the following 7 days
Trial: 24717908
Drug: Low-dose remifentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remifentanil (0.1 μg/kg/min)
Trial: 24717908
Drug: High-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose remifentanil (0.25 μg/kg/min)
Trial: 22824930
Drug: Ramipril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (2.5 mg for the first 3 days followed by 5 mg/day, reduced to 2.5 mg/day on the first postoperative day)
Trial: 16327967
Drug: Daily visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily visit from a communicator/facilitator
Trial: 11590503
Drug: Treatment combinations
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment combinations of registered antiretroviral drugs (specific regimens not detailed)
Trial: 29269937
Drug: Purified rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified rice endosperm protein (REP) supplementation (5 g/day for 4 weeks)
Trial: 25693609
Drug: Revexepride 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revexepride 0.1 mg three times daily
Trial: 25693609
Drug: Revexepride 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revexepride 0.5 mg three times daily
Trial: 25693609
Drug: Revexepride 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revexepride 2.0 mg three times daily
Trial: 20938767
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 μg/day) for up to 24 months